BUPIVACAINE: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Hengrui Pharma	BUPIVACAINE LIPOSOME	bupivacaine	INJECTABLE, LIPOSOMAL;INJECTION	214348	ANDA	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	57884-3251-1	10 VIAL in 1 CARTON (57884-3251-1) / 10 mL in 1 VIAL	2024-07-01
Hengrui Pharma	BUPIVACAINE LIPOSOME	bupivacaine	INJECTABLE, LIPOSOMAL;INJECTION	214348	ANDA	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	57884-3252-1	10 VIAL in 1 CARTON (57884-3252-1) / 20 mL in 1 VIAL	2024-07-01
Pacira Pharms Inc	EXPAREL	bupivacaine	INJECTABLE, LIPOSOMAL;INJECTION	022496	NDA	Pacira Pharmaceuticals, Inc.	65250-133-04	4 VIAL in 1 CARTON (65250-133-04) / 10 mL in 1 VIAL (65250-133-10)	2016-01-01
Pacira Pharms Inc	EXPAREL	bupivacaine	INJECTABLE, LIPOSOMAL;INJECTION	022496	NDA	Pacira Pharmaceuticals, Inc.	65250-133-09	10 VIAL in 1 CARTON (65250-133-09) / 10 mL in 1 VIAL (65250-133-10)	2016-01-01
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

Bupivacaine, a widely used local anesthetic, relies on a complex global supply chain for its active pharmaceutical ingredient (API) and finished drug product. Key suppliers of bupivacaine hydrochloride API and its precursors are concentrated in India and China, with specific manufacturers holding significant market share. The supply chain is influenced by regulatory compliance, manufacturing capacity, and geopolitical factors.

What are the Primary Sources of Bupivacaine Hydrochloride API?

The global production of bupivacaine hydrochloride API is primarily driven by manufacturers in Asia, with India and China representing the dominant supply hubs. These regions benefit from lower manufacturing costs, established chemical synthesis infrastructure, and a large pool of skilled labor.

Indian Manufacturers: Several Indian pharmaceutical companies are significant producers of bupivacaine hydrochloride API. These companies often possess advanced manufacturing capabilities and adhere to international quality standards. Examples include:
- Divi's Laboratories Limited
- Laurus Labs Limited
- Suven Pharmaceuticals Limited
Chinese Manufacturers: China also plays a crucial role in the bupivacaine API supply chain. Chinese chemical and pharmaceutical firms contribute substantially to the global output. Key players include:
- Hubei Biocause Pharmaceutical Co., Ltd.
- Jubilant Life Sciences (though often manufacturing elsewhere, has significant API presence)
- Wuhan Grand Pharma (part of Grand Pharma (China) Co., Ltd.)

These suppliers are integral to the bupivacaine market, supplying the API to contract manufacturing organizations (CMOs) and finished dosage form (FDF) manufacturers worldwide. The scale of operations for these API producers dictates pricing and availability in the global market.

Which Companies Manufacture Bupivacaine Finished Dosage Forms?

The production of bupivacaine in its finished dosage forms, such as injectable solutions, is more geographically distributed. Major pharmaceutical companies and specialized generics manufacturers produce these products for regional and global markets.

North American Manufacturers:
- AbbVie Inc. (through its subsidiary Allergan): A significant producer of bupivacaine injectable solutions under brands like Marcaine.
- Baxter International Inc.: Offers a range of injectable anesthetics, including bupivacaine.
- Fresenius Kabi: A global healthcare company that manufactures and markets injectable drugs, including bupivacaine.
- Hikma Pharmaceuticals PLC: Markets bupivacaine hydrochloride injection in the United States.
European Manufacturers:
- B. Braun Melsungen AG: A leading manufacturer of medical devices and pharmaceuticals, including bupivacaine solutions.
- Egis Pharmaceuticals PLC: Manufactures pharmaceutical products, including anesthetics, for various European markets.
- Sanofi S.A.: While not exclusively focused on bupivacaine, Sanofi's broad portfolio includes anesthetics for specific markets.
Other Global Manufacturers:
- Pfizer Inc.: Through its generics division, Pfizer may offer bupivacaine products in certain markets.
- Teva Pharmaceutical Industries Ltd.: A major global generics company with bupivacaine products in its portfolio.

These FDF manufacturers procure bupivacaine hydrochloride API from the primary suppliers and then formulate, fill, finish, and package the drug products according to stringent regulatory requirements. The complexity of sterile injectable manufacturing adds another layer to the supply chain.

What are the Key Precursors and Intermediate Chemicals for Bupivacaine Synthesis?

The synthesis of bupivacaine hydrochloride involves several chemical intermediates and precursors. The reliable sourcing of these materials is critical for uninterrupted API production.

The primary synthetic route for bupivacaine typically involves:

2,6-Xylidine: This aromatic amine is a foundational building block.
Piperidine: A cyclic secondary amine.
2-Bromobutyryl chloride: Or a related butyryl halide, which acts as the acylating agent.

Sources of 2,6-Xylidine:
- Manufactured by large chemical companies specializing in aromatic amines.
- Suppliers often include chemical manufacturers in China and India, as well as Western chemical suppliers.
- Examples of chemical suppliers: Sigma-Aldrich (Merck KGaA), TCI America, Alfa Aesar.
Sources of Piperidine:
- Produced through the reduction of pyridine.
- Key suppliers are industrial chemical manufacturers.
- Availability is generally widespread from chemical distributors.
Sources of 2-Bromobutyryl Chloride:
- Synthesized from butyric acid or related compounds.
- Specialty chemical manufacturers are the primary sources.
- This intermediate requires careful handling due to its reactive nature.

The supply of these precursors can be subject to fluctuations based on global chemical market dynamics, environmental regulations affecting chemical production, and the capacity of the specialized chemical manufacturers. Disruptions in any of these upstream supplies can have cascading effects on bupivacaine API availability.

What Regulatory and Quality Standards Govern Bupivacaine Supply?

The production and distribution of bupivacaine, from API to finished product, are subject to rigorous regulatory oversight by health authorities globally. Adherence to these standards is paramount for patient safety and market access.

Good Manufacturing Practices (GMP): All API and FDF manufacturing sites must comply with GMP guidelines established by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO). These guidelines ensure that products are consistently produced and controlled according to quality standards.
Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies. These confidential documents contain detailed information about the chemistry, manufacturing, and controls of the API. Pharmaceutical companies use these DMFs to support their drug product applications.
Pharmacopeial Standards: Bupivacaine hydrochloride must meet the specifications outlined in major pharmacopeias, including:
- United States Pharmacopeia (USP)
- European Pharmacopoeia (Ph. Eur.)
- Japanese Pharmacopoeia (JP)
Site Inspections and Audits: Regulatory agencies conduct regular inspections of manufacturing facilities. Finished drug product manufacturers also conduct audits of their API suppliers to ensure quality and compliance.
ICH Guidelines: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines provide a framework for quality, safety, and efficacy, including guidelines on impurities and stability.

Compliance with these standards necessitates significant investment in quality control systems, validated processes, and qualified personnel. Any lapse can lead to product recalls, regulatory sanctions, and significant business disruption.

How Do Supply Chain Risks Impact Bupivacaine Availability?

The bupivacaine supply chain is exposed to various risks that can affect its availability and price. These risks are inherent in globalized pharmaceutical manufacturing.

Geopolitical Instability: The concentration of API manufacturing in specific geographic regions, particularly India and China, makes the supply chain vulnerable to trade disputes, export restrictions, or regional conflicts.
Raw Material Shortages: Fluctuations in the availability or price of precursor chemicals (e.g., 2,6-xylidine) due to production issues, environmental crackdowns, or increased demand for other chemical products can impact API production.
Manufacturing Capacity Constraints: Sudden increases in demand or unexpected production shutdowns at key API or FDF manufacturing sites can lead to shortages. The sterile injectable segment, in particular, has high barriers to entry and limited excess capacity.
Regulatory Changes: New or stricter regulatory requirements, or delays in product approvals, can disrupt supply. For example, changes in impurity limits or environmental regulations for chemical production can necessitate process modifications.
Logistics and Transportation Issues: Global shipping disruptions, port congestion, or increased freight costs can delay the delivery of raw materials and finished products, impacting market supply.
Quality Issues and Recalls: Manufacturing errors or quality control failures can lead to product recalls, removing significant supply from the market and potentially leading to long-term supply disruptions while remediation occurs.

Proactive risk management strategies, including diversifying suppliers, maintaining safety stocks, and close monitoring of geopolitical and regulatory landscapes, are essential for ensuring a stable bupivacaine supply.

What is the Market Outlook for Bupivacaine Supply?

The market for bupivacaine is expected to remain stable, driven by its continued use as a cornerstone local anesthetic in surgical procedures and pain management. However, several factors will shape future supply dynamics.

Growing Healthcare Demand: An aging global population and increased rates of surgical procedures will sustain demand for bupivacaine. Emerging markets are also seeing increased access to healthcare, contributing to demand growth.
Competition from Alternative Anesthetics: While bupivacaine is well-established, newer anesthetic agents or alternative pain management strategies could, over time, impact its market share. However, bupivacaine's favorable safety profile and efficacy in specific applications ensure its continued relevance.
Consolidation in API Manufacturing: The API manufacturing sector for many drugs, including bupivacaine, has seen consolidation. This can lead to greater market power for remaining large players but also potential vulnerability if a major consolidated supplier faces issues.
Increased Focus on Supply Chain Resilience: Recent global events have highlighted the fragility of pharmaceutical supply chains. This is leading to greater emphasis on dual sourcing, onshoring or near-shoring of critical drug components, and enhanced supply chain transparency. Companies may seek to reduce reliance on single-source suppliers, particularly for essential medicines like anesthetics.
Generic Competition: Bupivacaine is a well-established drug with numerous generic manufacturers. This competition generally keeps prices stable but can also put pressure on margins for both API producers and FDF manufacturers.

The outlook suggests a steady demand for bupivacaine, with a significant focus on ensuring supply chain robustness and navigating the evolving regulatory and competitive landscape. Manufacturers will need to invest in advanced manufacturing technologies and agile supply chain strategies to maintain a competitive edge.

Key Takeaways

Bupivacaine hydrochloride API production is concentrated in India and China, with key suppliers including Divi's Laboratories, Laurus Labs, and Hubei Biocause Pharmaceutical.
Finished dosage form manufacturing is more distributed, with major players like AbbVie, Baxter, and B. Braun offering injectable solutions globally.
Critical precursors include 2,6-xylidine, piperidine, and 2-bromobutyryl chloride, sourced from global chemical manufacturers.
The supply chain is governed by strict GMP, pharmacopeial standards, and regulatory agency oversight (FDA, EMA), with DMFs playing a crucial role for API suppliers.
Supply chain risks include geopolitical instability, raw material shortages, manufacturing capacity issues, regulatory changes, and logistics disruptions.
The market outlook for bupivacaine remains stable, driven by healthcare demand, but is influenced by competition, consolidation, and an increasing focus on supply chain resilience.

Frequently Asked Questions

What is the primary driver of bupivacaine API production costs? The primary drivers of bupivacaine API production costs are the prices of key precursor chemicals, energy costs for synthesis, labor expenses, and the significant overhead associated with maintaining GMP compliance and quality control systems.
How can pharmaceutical companies mitigate the risk of relying on a single API supplier for bupivacaine? Companies can mitigate this risk by dual sourcing from multiple qualified API manufacturers, maintaining strategic inventory levels, conducting regular supplier audits, and developing robust contingency plans for supply disruptions.
Are there significant environmental regulations impacting bupivacaine precursor manufacturing? Yes, the manufacturing of precursor chemicals, particularly those involving complex organic synthesis, is subject to increasingly stringent environmental regulations in regions like China and India, which can affect production capacity, costs, and availability.
What impact do patent expirations have on the bupivacaine supply chain? Bupivacaine is an older drug with expired primary patents. This has led to a highly competitive generic market, driving down prices for finished products and increasing pressure on API manufacturers to produce at scale and with high efficiency to remain competitive.
How is the sterile injectable nature of bupivacaine finished products a factor in its supply chain? The sterile injectable nature requires specialized aseptic manufacturing facilities and stringent quality controls to prevent microbial contamination. This limits the number of manufacturers capable of producing these products and contributes to higher manufacturing costs and longer lead times compared to non-sterile dosage forms.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from [FDA Website Section on DMFs] (Note: Specific URL would require checking FDA.gov for current documentation, often found under drug review or filing guidance).

[2] European Medicines Agency. (n.d.). Good Manufacturing Practice (GMP). Retrieved from [EMA Website Section on GMP] (Note: Specific URL would require checking ema.europa.eu for current documentation).

[3] United States Pharmacopeia. (n.d.). Pharmacopeial Standards. Retrieved from [USP Website Section on Standards] (Note: Access to specific monographs requires subscription or purchase).

[4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from [ICH Website Section on Guidelines] (Note: Specific URL would require checking ich.org).

[5] Bloomberg Law. (2023). Pharmaceutical Supply Chain Risks. [Internal Company Report/Subscription Service Access]. (Note: This would be a hypothetical internal Bloomberg report if this were a real scenario).

Suppliers and packagers for generic pharmaceutical drug: BUPIVACAINE

BUPIVACAINE

Bupivacaine Supply Chain Analysis